Funding for Researchers
Neuroendocrine research grant types
NETRF offers four different neuroendocrine cancer research grants ( Accelerator, Investigator, Pilot, and Mentored Awards) with cancer research grants ranging from $100,000 to $1.2 million.
Seeking transformational ideas
We invite innovative and transformative research proposals in NETs to help bring the field closer to more effective therapies. We are equally interested in basic, translational and clinical research applications, and encourage collaborations between investigators with expertise in different fields.
Encouraging team science
We are very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts in bioinformatics, bio-nanotechnology, or other relevant disciplines. Proposals that cover promising and potentially transferable mechanisms and/or technologies, which have been applied successfully to other areas of cancer research, are highly desirable and will be evaluated based on their level of applicability to NETs.
Areas of interest
Some areas of interest include but not limited to:
- Application of existing or new technologies to target NETs
- New/optimized experimental models
- Cancer metabolism
- Deciphering the molecular underpinnings of NETs
- Diagnostics
- Clinical Research
- Cell invasion and metastasis
- Immune microenvironment
- Nuclear medicine, theranostics, imaging
We invite also proposals that cover promising and potentially transferable technologies, which have been applied successfully to other areas of cancer.
Organs of interest
While we recognize that neuroendocrine cancers can develop in many different organs, our focus includes:
GEP-NETs
We continue to have an interest and fund applications proposing to study all aspects of gastro-entero-pancreatic NETs, including sites of metastasis.
Lung Carcinoids
We are interested in funding work in well-differentiated, low-grade typical carcinoids (TCs), well-differentiated, intermediate-grade atypical carcinoids (ACs), or diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH).
Currently, the lung fund does not extend to SCLC, LCLC, non-SCLC, squamous cell carcinomas, adenocarcinomas, mesotheliomas or poorly differentiated non–small cell lung carcinomas.
Expanding the field
Prior research in NETs is not a prerequisite. We encourage expert cancer scientists to enter the NET research field. However, such candidates must demonstrate a commitment to continue with NET research.
See our FAQ for more information.